Activist Investor to Push Avantor to Sell Itself
Engine Capital has a roughly 3% stake in the life-sciences company.
AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y
Avantor stock dips more than 15% as Q2 EPS missed estimates, revenue declines year over year and lowers full-year guidance.
Avantor, Inc. (AVTR) Q2 2025 Earnings Call Transcript
Avantor, Inc. (NYSE:AVTR ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants Allison K. Hosak - Senior VP of Global Communications & Brand Michael Stubblefield - President, CEO & Director R.
Avantor (AVTR) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago.
Avantor: Unloved Lab And Medical Testing Supplier Under Heavy Accumulation
Avantor is trading at its lowest valuation since 2019, attracting significant management buying of the stock, with clear chart accumulation trends since April. AVTR has been aggressively repaying debt, selling assets and restructuring operations, aiming for $400-500 million in annual savings by late 2026, especially if sales rebound. Risks include potential trade tariffs, U.S. healthcare research spending cuts, and recession, but insider votes of confidence (share buying) suggest a bullish outlook for new investment.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
Avantor: A Healthier Diagnosis As Expectations Cool
Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio.
Avantor Stock Plummets as Firm's CEO Set to Leave Amid Sales Slump, Outlook Cut
Avantor (AVTR) shares sank 16% Friday after the maker of lab chemicals and other life sciences products announced its CEO was resigning, reported weaker-than-expected net sales as government spending fell, and slashed its guidance.
Avantor, Inc. (AVTR) Q1 2025 Earnings Call Transcript
Avantor, Inc. (NYSE:AVTR ) Q1 2025 Earnings Call April 25, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications and Brand Michael Stubblefield - President and CEO R. Brent Jones - EVP and CFO Conference Call Participants Michael Ryskin - Bank of America Securities Vijay Kumar - Evercore ISI Rachel Vatnsdal - J.P.
Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Avantor (AVTR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.
